Johnson & Johnson expects $2.5 billion in global sales from Covid vaccine this year


In this article

In this photo illustration a Johnson & Johnson logo is seen in front of a medical syringe and a vial with coronavirus vaccine.
Pavlo Gonchar | SOPA Images | LightRocket | Getty Images

Johnson & Johnson said Wednesday it expects to sell $2.5 billion of its Covid-19 vaccine, even as concerns mount over the shot’s effectiveness against the delta variant.

In releasing its second-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations.

Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

  • Adjusted EPS: $2.48 per share vs $2.27 expected.
  • Revenue: $23.31 billion vs $22.21 billion expected.

The company’s share price was up nearly 1% in premarket trading following the report.

This is a developing story. Please check back for updates.


Products You May Like

Articles You May Like

More than half of adults have unused gift cards. Here’s how to make sure you don’t lose that money
Tuition insurance may help cover costs if a student withdraws from college
Elizabeth Warren makes fresh push for wealth tax – ‘Yes, Jeff Bezos, I’m looking at you’
Stocks making the biggest moves premarket: Skechers, Boston Beer, Snap, Twitter & more
Stock futures are flat ahead of Big Tech earnings

Leave a Reply

Your email address will not be published. Required fields are marked *